395 related articles for article (PubMed ID: 27638367)
1. Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse.
Kenderian SS; Porter DL; Gill S
Biol Blood Marrow Transplant; 2017 Feb; 23(2):235-246. PubMed ID: 27638367
[TBL] [Abstract][Full Text] [Related]
2. Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia.
Tasian SK; Kenderian SS; Shen F; Ruella M; Shestova O; Kozlowski M; Li Y; Schrank-Hacker A; Morrissette JJD; Carroll M; June CH; Grupp SA; Gill S
Blood; 2017 Apr; 129(17):2395-2407. PubMed ID: 28246194
[TBL] [Abstract][Full Text] [Related]
3. At The Bedside: Clinical review of chimeric antigen receptor (CAR) T cell therapy for B cell malignancies.
Oluwole OO; Davila ML
J Leukoc Biol; 2016 Dec; 100(6):1265-1272. PubMed ID: 27354412
[TBL] [Abstract][Full Text] [Related]
4. At the Bench: Chimeric antigen receptor (CAR) T cell therapy for the treatment of B cell malignancies.
Daniyan AF; Brentjens RJ
J Leukoc Biol; 2016 Dec; 100(6):1255-1264. PubMed ID: 27789538
[TBL] [Abstract][Full Text] [Related]
5. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
6. Building upon the success of CART19: chimeric antigen receptor T cells for hematologic malignancies.
Rotolo A; Karadimitris A; Ruella M
Leuk Lymphoma; 2018 Sep; 59(9):2040-2055. PubMed ID: 29165008
[TBL] [Abstract][Full Text] [Related]
7. Chimeric Antigen Receptor T Cell Therapy in Hematology.
Ataca P; Arslan Ö
Turk J Haematol; 2015 Dec; 32(4):285-94. PubMed ID: 26377367
[TBL] [Abstract][Full Text] [Related]
8. Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells.
Allegra A; Innao V; Gerace D; Vaddinelli D; Musolino C
Blood Cells Mol Dis; 2016 Nov; 62():49-63. PubMed ID: 27865176
[TBL] [Abstract][Full Text] [Related]
9. Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies.
Kebriaei P; Huls H; Jena B; Munsell M; Jackson R; Lee DA; Hackett PB; Rondon G; Shpall E; Champlin RE; Cooper LJ
Hum Gene Ther; 2012 May; 23(5):444-50. PubMed ID: 22107246
[TBL] [Abstract][Full Text] [Related]
10. What is the Role of Hematopoietic Cell Transplantation (HCT) for Pediatric Acute Lymphoblastic Leukemia (ALL) in the Age of Chimeric Antigen Receptor T-Cell (CART) Therapy?
Taraseviciute A; Broglie L; Phelan R; Bhatt NS; Becktell K; Burke MJ
J Pediatr Hematol Oncol; 2019 Jul; 41(5):337-344. PubMed ID: 30973486
[TBL] [Abstract][Full Text] [Related]
11. Stop and go: hematopoietic cell transplantation in the era of chimeric antigen receptor T cells and checkpoint inhibitors.
Ghosh A; Politikos I; Perales MA
Curr Opin Oncol; 2017 Nov; 29(6):474-483. PubMed ID: 28872470
[TBL] [Abstract][Full Text] [Related]
12. T-cell-based Immunotherapies for Haematological Cancers, Part B: A SWOT Analysis of Adoptive Cell Therapies.
Rallis KS; Hillyar CRT; Sideris M; Davies JK
Anticancer Res; 2021 Mar; 41(3):1143-1156. PubMed ID: 33788705
[TBL] [Abstract][Full Text] [Related]
13. Donor origin CAR T cells: graft versus malignancy effect without GVHD, a systematic review.
Anwer F; Shaukat AA; Zahid U; Husnain M; McBride A; Persky D; Lim M; Hasan N; Riaz IB
Immunotherapy; 2017 Jan; 9(2):123-130. PubMed ID: 28128714
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy in hematologic malignancies: past, present, and future.
Im A; Pavletic SZ
J Hematol Oncol; 2017 Apr; 10(1):94. PubMed ID: 28434396
[TBL] [Abstract][Full Text] [Related]
15. The what, when and how of CAR T cell therapy for ALL.
Frey N
Best Pract Res Clin Haematol; 2017 Sep; 30(3):275-281. PubMed ID: 29050700
[TBL] [Abstract][Full Text] [Related]
16. Use of chimeric antigen receptor T cells in allogeneic hematopoietic stem cell transplantation.
Liu J; Zhang X; Zhong JF; Zhang C
Immunotherapy; 2019 Jan; 11(1):37-44. PubMed ID: 30702011
[TBL] [Abstract][Full Text] [Related]
17. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.
Alabanza L; Pegues M; Geldres C; Shi V; Wiltzius JJW; Sievers SA; Yang S; Kochenderfer JN
Mol Ther; 2017 Nov; 25(11):2452-2465. PubMed ID: 28807568
[TBL] [Abstract][Full Text] [Related]
18. Anti-CD123 chimeric antigen receptor T-cells (CART): an evolving treatment strategy for hematological malignancies, and a potential ace-in-the-hole against antigen-negative relapse.
Cummins KD; Gill S
Leuk Lymphoma; 2018 Jul; 59(7):1539-1553. PubMed ID: 28901790
[TBL] [Abstract][Full Text] [Related]
19. The Role of Co-stimulatory/Co-inhibitory Signals in Graft-vs.-Host Disease.
Kumar S; Leigh ND; Cao X
Front Immunol; 2018; 9():3003. PubMed ID: 30627129
[TBL] [Abstract][Full Text] [Related]
20. Chimeric Antigen Receptor T-Cell Therapy for Chronic Lymphocytic Leukemia: A Narrative Review.
Mato AR; Thompson MC; Nabhan C; Svoboda J; Schuster SJ
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):852-856. PubMed ID: 28826693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]